Medication Changes After Renal Denervation: Current Evidence and Patient Perspectives Authors: Zhipeng Zhang, Fei Zhao, Runyu Ye, Xin Zhang, Yong Peng, Xiaoping Chen, Kai Liu Published: 2024 ABSTRACT Renal denervation (RDN) is recognized as an adjunct therapy for hypertension management with a favorable and consistent blood pressure–lowering efficacy and safety profile. Alteration in medication burden is another noteworthy outcome of RDN for clinicians and patients. In this review, we summarized current clinical trials and patient perspectives, focusing on the use of antihypertensive medication (AHM) after RDN. The results of randomized controlled trials demonstrated that patients undergoing RDN exhibited lower blood pressure levels with a similar AHM burden or similar blood pressure levels with fewer AHMs than the sham control group. In studies with follow‐ups of ≤6 months, AHM use increased or remained generally consistent in patients undergoing RDN, which may be attributed to the prespecified study process. In studies with follow‐ups of >6 months, the blood pressure–lowering efficacy of RDN was consistent with a decreasing or similar AHM burden compared with baseline conditions, except for the 36‐month results in the SPYRAL HTN‐ON MED (Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications) trial. Huge gaps exist between current evidence on medication changes after RDN and patient expectations, which may be addressed through adequate communication in a shared decision‐making process and further improvement of the RDN procedure. Moreover, novel evaluation methodologies for assessing medication burden changes, incorporating adherence to AHMs and modifications in drug classes, may be required to evaluate the impact of RDN on medication usage in the future. Nonstandard Abbreviations and Acronyms antihypertensive medication Global SYMPLICITY Registry Global SYMPLICITY Registry Denervation Findings in Real World Endovascular Ultrasound Renal Denervation to Treat Hypertension Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill A Study of the ReCor Medical Paradise System in Stage II Hypertension renal denervation Efficacy and Safety of Sympathetic Mapping and Ablation of Renal Nerves for the Treatment of Hypertension Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications A Controlled Trial of RDN for Resistant Hypertension Effect of Alcohol‐Mediated RDN on Blood Pressure in the Presence of AHMs Alcohol‐Mediated RDN in Patients With Hypertension in the Absence of AHMs Uncontrolled arterial hypertension is one of the leading cardiovascular disorders, affecting 1.28 billion adults aged 30 to 79 years worldwide. 1 Antihypertensive medications (AHMs) are effective in preventing cardiovascular events in patients with hypertension 2 ; however, the benefits are compromised by poor adherence. A meta‐analysis revealed that approximately half of the patients withdrew AHM after a 1‐year follow‐up. 3 Medication compliance decreased with the increase in the number of tablets. 4 For decades, there have been high hopes for the application of device therapy to address poor adherence to AHM to reduce the number of tablets. In recent multicenter randomized and sham‐controlled trials, minimally invasive catheter‐based renal denervation (RDN) using radiofrequency or ultrasound‐based energy exhibited significant blood pressure (BP)‐lowering efficacy and safety profiles in treated or untreated patients with hypertension. 5 Long‐term efficacy of BP reduction after RDN was sustained for up to 36 months in randomized sham‐controlled trials and for 10 years in observational cohort studies with favorable renal safety, 6 providing an alternative treatment option for patients with poor compliance and drug intolerance. However, most patients still require AHM to achieve better BP control after RDN. Patient preference studies demonstrated that medication burden changes after RDN may significantly influence a patient's choice of treatment modality. 7 , 8 An Internet‐based survey of 1000 US residents aged ≥30 years demonstrated that 30% of adults would rather risk a shorter life than take medicine daily for cardiovascular disease prevention. 9 Moreover, changes in AHM burden were proposed as another clinical end point in device‐based therapies, 10 which is of particular importance to both physicians and patients. Herein, we summarize the current evidence on medication burden changes after RDN and address its differences with patient expectations. Trials SPYRAL HTN‐ON MED Trial SPYRAL HTN‐ON MED (Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications) is a global, multicenter, randomized, blinded, sham‐controlled trial to assess the safety and efficacy of catheter‐based radiofrequency RDN in the presence of AHM. 11 Patients aged 20 to 80 years with uncontrolled hypertension receiving 1 to 3 stable doses of AHM for at least 6 weeks were enrolled and randomly assigned to undergo RDN using the Symplicity Spyral multielectrode RDN catheter (Symplicity Spyral catheter, Medtronic) or a sham control group. In the earlier SPYRAL HTN‐ON MED pilot study, 12 the BP reduction was significantly greater in the RDN group (n=38) than in the sham group (n=42) at 6 months with similar numbers of AHMs (2.13±1.40 versus 2.21±1.05, P=0.17). Moreover, adherence to AHMs was similar between the 2 groups at 6 months (60.5% versus 64.3%, P=0.82). The pooled results of the SPYRAL HTN‐ON MED trial, 11 including pilot and expansion cohorts, and using a Bayesian trial design revealed that the treatment difference in mean 24‐hour ambulatory systolic blood pressure (SBP) between the RDN and sham groups was −1.9 mm Hg (95% CI, −4.4 to 0.5 mm Hg; P=0.12), not meeting the primary efficacy end point. However, patients in the RDN group exhibited a significantly greater reduction in office SBP and ambulatory nighttime SBP compared with those in the sham group (treatment difference, −4.9 mm Hg [95% CI: −7.9 to −1.9 mm Hg]; P=0.0015; and −3.7 mm Hg [95% CI, −6.5 to −0.9 mm Hg]; P=0.0095, respectively). In relation to drug use, both groups exhibited 60% adherence to AHM at 6 months. Patients in the RDN group were prescribed fewer numbers of AHMs compared with the sham group at 6 months (1.9±0.9 versus 2.1±0.9, P=0.0085). The medication burden was also higher in the sham group than in the RDN group (3.5±3.2 versus 2.9±2.7, P=0.043) at 6 months. Drug testing indicated that the AHM burden increased from baseline to 6 months in 34 (17%) patients in the RDN group, while it decreased in 33 (16%) patients. In the sham control group, the AHM burden increased in 34 (26%) patients after 6 months, while it decreased in 13 (10%) patients. The AHM classes were similar between groups at baseline and 6 months, while the use of diuretics decreased in both groups at 6 months. For patients undergoing RDN, the number of AHMs and AHM burden were almost similar from baseline to 6 months (number of AHMs, 1.9±0.8 versus 1.9±0.9; AHM burden, 2.8±2.5 versus 2.9±2.7). Furthermore, Townsend et al 13 compared AHM and BP changes among prespecified subpopulations. Based on the minimal AHM changes between treatment groups, patients outside the United States exhibited significant office and ambulatory BP reductions compared with the sham group, whereas BP changes were similar between the RDN and sham groups in the US population. Within the US cohort, Black Americans in the sham group exhibited a significant increase in the AHM burden from baseline through 6 months (P=0.003), which may have diluted the treatment effect in the combined population. The BP‐lowering efficacy and safety of the SPYRAL HTN‐ON MED proof‐of‐concept study was reported to persist for up to 36 months. 14 Despite a similar AHM burden, the long‐term results revealed a greater progressive decline in BP over time in patients undergoing RDN compared with the sham procedure, with a favorable safety profile. The mean ambulatory BP decreased by −18.7/−11.9 mm Hg in the RDN group and −8.6/−6.0 mm Hg in the sham control group at 36 months (adjusted between‐group SBP difference: −10.0 mm Hg [95% CI, −16.6 to −3.3 mm Hg]; P=0.039; adjusted between‐group diastolic BP difference: −5.9 mm Hg [95% CI, −10.1 to −1.8 mm Hg]; P=0.0055). Patients in the RDN group were prescribed 3.03±1.20 AHMs, compared with 3.05±1.43 AHMs for patients in the sham group (P=0.76) at 36 months. The AHM burden at 36 months was also similar between the 2 groups (2.13±1.15 versus 2.55±2.19, P=0.26). At 36 months, 77% of patients in the RDN group and 93% in the sham control group adhered to medication. For patients undergoing the RDN procedure, the number of AHMs increased from 2.13±1.40 at baseline to 3.03±1.20 at 36 months, while the AHM burden increased from 1.43±1.19 at baseline to 2.13±1.15 at 36 months. RADIANCE‐HTN Trials The safety and BP‐lowering efficacy of endovascular ultrasound‐based RDN with or without concomitant AHM use in patients with mild‐to‐moderate hypertension or resistant hypertension were assessed in the RADIANCE‐HTN trials. Patients aged 18 to 75 years with various degrees of hypertension severity were included in the international, multicenter, randomized, and sham‐controlled trials conducted in the United States and Europe. In the RADIANCE‐HTN SOLO (Endovascular Ultrasound Renal Denervation to Treat Hypertension) 15 and RADIANCE II (A Study of the ReCor Medical Paradise System in Stage II Hypertension) 16 trials, patients with office BP ≥140/90 mm Hg but <180/110 mm Hg on 0 to 2 AHMs were eligible. They were instructed to discontinue all AHMs for 4 weeks to establish a stable baseline BP without medication. After a 4‐week washout period, patients with daytime ambulatory BP ≥135/85 mm Hg and <170/105 mm Hg and suitable renal artery anatomy were randomly assigned to undergo RDN using the Paradise Renal Denervation System (ReCor Medical) or a sham procedure in a 1:1 (RADIANCE‐HTN SOLO) or 2:1 (RADIANCE II) ratio. In the RADIANCE‐HTN TRIO (Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill) study, 17 patients were switched to a once‐daily, single‐pill, fixed‐dose, triple combination of amlodipine 10 mg (or 5 mg in patients with severe leg edema), valsartan 160 mg (or olmesartan 40 mg), and hydrochlorothiazide 25 mg at enrollment. After a 4‐week standardized drug treatment, patients with ambulatory daytime BP ≥135/85 mm Hg and a suitable renal artery anatomy were randomized (1:1) to undergo RDN or a sham procedure. The primary efficacy end point was the change in daytime ambulatory SBP from baseline to 2 months. After determining the primary end point at month 2, a prespecified standardized stepped‐care antihypertensive treatment was sequentially added if the monthly measured home BP was ≥135/85 mm Hg in the subsequent 4 months to improve BP control in continued blinding conditions. After 6 months, the individual AHM regimen was at the physician's discretion. At 2 months, the endovascular ultrasound‐based RDN with the Paradise Renal Denervation System significantly reduced daytime ambulatory SBP reduction in the RDN group compared with the sham procedure in all three RADIANCE‐HTN trials (RADIANCE‐HTN SOLO: baseline‐adjusted difference between groups, −6.3 mm Hg [95% CI, −9.4 to −3.1]; P=0.0001; RADIANCE‐HTN TRIO: median between‐group difference, −4.5 mm Hg [95% CI, −8.5 to −0.3]; adjusted P=0.022; RADIANCE II: baseline‐adjusted between‐group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2]; P<0.001). The results of a patient‐level pooled analysis of RADIANCE‐HTN trials 18 indicated a greater reduction in ambulatory daytime SBP between groups across hypertension severity (mean −5.9 mm Hg [95% CI, −8.1 to −3.8 mm Hg; P<0.001) and was consistent across prespecified subgroups. The adherence rate to combination medications was 82% in both groups in the RADIANCE‐HTN TRIO trial at 2 months. In the RADIANCE‐HTN SOLO study, ambulatory daytime SBP decreased by −18.1 mm Hg among patients treated with RDN and by −15.6 mm Hg among patients treated with sham procedure at 6 months (mean between‐group difference adjusted for baseline BP: −2.3 mm Hg [95% CI, −6.0 to 1.5]; P=0.242; mean between‐group difference adjusted for baseline BP and number of AHMs, −4.3 mm Hg [95% CI, −7.9 to −0.6]; P=0.024). 19 AHM treatment was less intensive in the RDN group, with an average number of AHMs 0.9±0.9 in the RDN group and 1.3±0.9 in the sham group (P=0.010). The defined daily dose ratio was 1.3±1.5 in the RDN group and 2.0±1.8 in the sham group (P=0.018). The AHM load index was 0.5±0.5 in the RDN group and 0.7±0.6 in the sham group (P=0.014). In particular, 65.2% of patients in the RDN group received addition of AHMs after RDN, lowering ambulatory daytime SBP from 150.2 to 132.2 mm Hg, although the proportion in the sham group was 84.5% (P=0.008). Adherence was not assessed by measuring drug levels in patients' urine or plasma at 6 months. In the RADIANCE‐HTN TRIO study, 20 ambulatory daytime SBP decreased by 11.8 mm Hg in the RDN group and 12.3 mm Hg in the sham group at 6 months. The overall change in daytime ambulatory SBP was −2.5 mm Hg lower in the RDN than in the sham group (95% CI, −6.7 to 1.7 mm Hg; P=0.25). Patients in the RDN group received fewer AHMs from baseline to 6 months compared with the sham group (0.7±1.0 versus 1.1±1.1, P=0.045). Full adherence was achieved in 71.4% of the patients in the RDN group and 78.2% in the sham group (P=0.41). Spironolactone was the most frequently added AHM in the standardized stepped‐care antihypertensive treatment, and the proportion of spironolactone use was significantly lower in the RDN group (40.0% versus 60.9%, P=0.02). A recent patient‐level pooled analysis 21 using data from RADIANCE‐HTN SOLO, RADIANCE‐HTN TRIO, and RADIANCE II trials demonstrated the favorable BP‐lowering efficacy of ultrasound‐based RDN compared with sham with fewer AHMs. The baseline‐adjusted decrease in ambulatory daytime SBP at 6 months between RDN and sham groups was −1.9 mm Hg (95% CI, −4.8 to 1.0 mm Hg; P=0.33), and the difference in BP reduction was −3.0 mm Hg (95% CI, −5.7 to −0.2 mm Hg; P=0.033) after further adjusting for AHM. The changes in medication burden were smaller in the RDN group than the sham group from baseline to 6 months (changes in number of AHMs, 1.1±1.0 versus 1.3±1.0; P=0.001; changes in defined daily dose, 1.3±1.6 versus 1.6±1.6; P=0.001; change in AHM load index, 0.5±0.6 versus 0.6±0.6; P=0.001). Full adherence to AHMs was achieved in 83.3% of the patients in the RDN group and 83.8% in the sham group (P=0.47). Notably, 66.3% of patients in the RDN group were added with ≥1 medication from baseline to 6 months, while the proportion was 77.0% in the sham group (P=0.002). At 12 months, 65 of 74 (87.8%) patients undergoing RDN and 67 of 72 (93.1%) patients in the sham control group completed ambulatory BP measurements in the RADIANCE‐HTN SOLO trial. The daytime ambulatory SBP was reduced by −16.5±12.9 mm Hg in the RDN group versus −15.8±13.1 mm Hg in the sham group (between‐group difference adjusted for baseline BP and number of AHM, −2.3 mm Hg [95% CI, −5.9 to 1.3 mm Hg]; P=0.201). 22 The reduction in office SBP was higher in the RDN group than in the sham group (adjusted between‐group difference, −6.3 mm Hg [95% CI, −11.1 to −1.5 mm Hg]; P=0.010). The RDN group exhibited a lower AHM number, defined daily dose, and antihypertensive load index than the sham control group (P=0.015, 0.007 and 0.009, respectively). Compared with the initial status at screening, the number of AHMs in the RDN group reduced from 1.2±0.7 to 1.0±0.8 at 12 months, the defined daily dose reduced from 1.9±2.3 to 1.4±1.4, and the antihypertensive load index reduced from 0.7±1.0 to 0.5±0.5. At 24 months, 51 of 69 (74%) patients randomized initially to the RDN group, and 49 of 67 sham patients (73%) completed their 24‐month follow‐ups in the RADIANCE‐HTN TRIO trial. 23 The office BP in the RDN group was reduced by −14.6/−8.4 mm Hg from screening (P<0.001 for both) and −9.3/−5.0 mm Hg from baseline (P=0.006 and P=0.02). A win‐ratio analysis comparing RDN and sham was used with prioritized hierarchical end points in the following order: reduction in office SBP ≥10 mm Hg, controlled office SBP<140 mm Hg, aldosterone antagonist use, and the defined daily dose of AHM. The win ratio was 1.5 at 24 months, favoring RDN (P=0.03). The mean number of AHMs in the RDN group were 3.9 at screening and 3.4 at 24 months. Using aldosterone antagonists was less frequent in the RDN group than in the sham group (39% versus 61%; P=0.03). In the RADIANCE‐HTN SOLO trial, 24 51 of 74 patients in the RDN group completed the 36‐month follow‐ups with available office BP data at 36 months, and 33 patients in the sham group crossed over to the RDN group, leaving only 20 patients in the sham group with available data, which were insufficient for a comparison. Office SBP was reduced by −17.7 mm Hg from baseline to 36 months with an additional 1.3 AHMs. From screening before medication washout to 36 months, office SBP was reduced by −8.4 mm Hg with a similar number of AHMs (1.2±0.7 versus 1.3±0.8, P=0.461). The proportion of patients prescribed calcium channel blockers increased from 23.5% to 52.9%, the use of angiotensin receptor blockers slightly increased, and the use of angiotensin‐converting enzyme inhibitors decreased. No patients were prescribed α1 and β receptor blockers at 36 months. TARGET BP Trials Evidence of alcohol‐mediated perivascular RDN in treating hypertension is significantly infrequent compared with procedures using radiofrequency and ultrasound energy. The TARGET BP trials are international, multicenter, randomized, blinded, sham‐controlled trials aiming to evaluate the safety and efficacy of alcohol‐mediated RDN using the Peregrine Catheter (0.6 mL per renal artery) for the treatment of uncontrolled hypertension in patients (aged 18–80 years) off (TARGET BP OFF‐MED [Alcohol‐Mediated RDN in Patients With Hypertension in the Absence of AHMs]) or on AHM (TARGET BP I [Effect of Alcohol‐Mediated RDN on Blood Pressure in the Presence of AHMs]). The TARGET BP OFF‐MED trial included patients with an ambulatory SBP of 135 to 170 mm Hg, an office SBP of 140 to 180 mm Hg, and a diastolic BP ≥90 mm Hg on 0 to 2 AHMs. 25 After a 4‐week medication washout period, patients were randomized (1:1) to either the alcohol‐mediated RDN or the sham control group. The primary efficacy outcome was the change in ambulatory SBP from baseline to 8 weeks. According to the study protocol, a blinded, prespecified AHM titration treatment was introduced from 8 weeks to 12 months after determining the primary end point. A total of 106 patients were randomized (1:1) to undergo RDN (n=50) or renal angiography sham procedure (n=56). At 8 weeks, ambulatory SBP was reduced by −2.9±7.4 mm Hg (P=0.009) in the RDN group and −1.4±8.6 mm Hg (P=0.25) in the sham group (between‐group difference, 1.5 mm Hg [95% CI, −4.8 to 1.7 mm Hg]; P=0.27). After medication escalation, both groups exhibited similar ambulatory SBP (RDN, 134.1±11.6 mm Hg versus sham, 135.1±11.7 mm Hg; P=0.696) and office SBP (RDN, 146.1±16.4 mm Hg versus sham, 145.7±14.3 mm Hg; P=0.724) at 6 months. The mean number of AHMs (0.96 versus 1.40, P=0.035), defined daily doses (1.20 versus 2.00, P=0.012), and proportion of patients on ≥2 AHMs (26% versus 52%, P=0.009) were lower in the RDN group than in the sham control group at 6 months. At 12 months, ambulatory SBP decreased by −10.6 mm Hg in patients treated with RDN and by −15.9 mm Hg in patients treated with the sham procedure (between‐group difference, 5.3 mm Hg [95% CI, −0.1 to 10.7]; P=0.0775). Office SBP decreased by −11.0 mm Hg in the RDN group and −13.2 mm Hg in the sham group (between‐group difference, 2.2 mm Hg [95% CI, −4.5 to 8.9]; P=0.6823). The mean number of AHMs (1.10 versus 1.60, P=0.0081), defined daily doses (1.50 versus 2.30, P=0.0168), and proportion of patients on ≥2 AHMs (29% versus 57%, P=0.005) were lower in the RDN group than the sham control group at 12 months. The 2 most frequently used AHMs were calcium channel blockers and angiotensin II receptor blockers in the RDN (46.0% and 30.0%, respectively) and sham (39.3% and 46.4%, respectively) groups. Compared with the use of AHM at screening, the use of calcium channel blockers at 12 months increased in both groups (RDN, 32.0%–46.0%; sham, 25.0%–39.3%), while angiotensin II receptor blocker use increased in the sham control group (33.9%–46.4%) and decreased in the RDN group (36.0%–30.0%). Recently, Kandzari et al presented the primary results of the TARGET BP I trial at the ACC 2024 meeting. 26 The TARGET BP I trial enrolled patients with office SBP 150 to 180 mm Hg, diastolic BP ≥90 mm Hg and mean ambulatory SBP 135 to 170 mm Hg while prescribing stable 2 to 5 AHMs. The primary outcome was baseline‐adjusted changes in mean ambulatory SBP at 3 months. In total, 301 patients from 99 centers in nine countries were randomized (1:1) to undergo alcohol‐mediated RDN (n=148) or renal angiography (n=153). At 3 months, mean ambulatory SBP reduced by −10.0±14.2 mm Hg in the RDN group and −6.8±12.1 mm Hg in the sham group (between‐group difference, −3.2 mm Hg [95% CI, −6.3 to 0 mm Hg]; P=0.0487). The changes in office SBP were similar between RDN and sham groups (between‐group difference, −3.0 mm Hg [95% CI, −7.0 to 1.0 mm Hg]; P=0.173). There was no difference in the dose titration score, defined daily dose, and medication index between the groups at 3 months. Moreover, no notable change was observed in the prescribed AHMs from baseline to 3 months. The adherence rates in the RDN and sham control groups were 51% and 49%, respectively (P=0.765). SMART Trial The SMART (Efficacy and Safety of Sympathetic Mapping and Ablation of Renal Nerves for the Treatment of Hypertension) trial is a multicenter, randomized, sham‐controlled trial to evaluate the safety and efficacy of targeted RDN in patients with uncontrolled hypertension using renal nerve mapping/selective ablation system developed by SyMap Medical Ltd (Suzhou), China, capable of mapping renal sympathetic/parasympathetic nerve sites and selectively removing renal sympathetic nerves. 27 , 28 The trial enrolled patients aged 18 to 65 years with uncontrolled hypertension and a history of hypertension for >6 months. After at least 4 weeks of standard AHM treatment, 220 patients with an office SBP of 150 to 180 mm Hg were randomized (1:1) to undergo selective RDN or sham procedures. The medication treatment in both groups was adjusted according to the predefined AHM titration protocol during the study. The primary efficacy end point included the control rate of office SBP (<140 mm Hg) and the change in the composite index of AHM at 6 months. The results revealed a similar control rate of office SBP in the RDN and sham groups at 6 months (95.4% versus 92.7%, P=0.429). The ambulatory SBP was reduced by −10.8 mm Hg in the RDN group and −10.0 in the sham group (P=0.685). The change in the antihypertensive drug composite index in the RDN group (9.17 at baseline to 13.16 at 6 months) was significantly lower than that in the sham group (9.04 at baseline to 16.03 at 6 months) (composite index change, 4.37 versus 7.61, P<0.01). Medication adherence was 89.9% in the RDN group and 90.9% in the sham group at 6 months. The SMART trial differs from previous RDN trials in using combined primary end points, including the control rate of office BP and changes in AHM burden. The trial demonstrated that mapping/selective RDN reduced the drug burden with less ablation of renal arteries, which is a critically meaningful question in clinical practice. Further research is required to determine whether AHM use could be reduced in patients undergoing mapping/selective RDN in the long term. SYMPLICITY HTN‐3 Trial The SYMPLICITY HTN‐3 (A Controlled Trial of RDN for Resistant Hypertension) is a prospective, multicenter, sham‐controlled, randomized clinical trial to evaluate the efficacy and safety of catheter‐based RDN in patients aged 18 to 80 years with drug‐resistant hypertension. SYMPLICITY HTN‐3 is the first randomized, sham‐controlled trial in the catheter‐based RDN era, and its design has been reported previously. 29 Eligible patients were randomly assigned (2:1) to undergo RDN or a sham procedure. The primary efficacy end point was not met at 6 months, but the early safety of the Symplicity RDN catheter was confirmed. The effects of RDN in this trial were complicated by many factors, including variations in the procedural methods and medication changes. Subsequently, the efficacy of RDN has been extensively investigated in numerous randomized sham‐controlled trials. The final report of SYMPLICITY HTN‐3 30 indicated that office SBP decreased by −26.4 mm Hg in the RDN group and −5.7 mm Hg in the sham control group (adjusted treatment difference −22.1 mm Hg [95% CI: −27.2 to −17.0], P≤0.0001) at 36 months. Ambulatory SBP reduced by −15.6 mm Hg in the RDN group and by −0.3 mm Hg in the sham group (adjusted treatment difference, −16.5 mm Hg [95% CI: −20.5 to −12.5]; P≤0.0001). Medication levels were not determined in this trial. At baseline, patients in the RDN group were prescribed medication from 4.9 (±1.2) antihypertensive classes versus 5.0 (±1.2) antihypertensive classes for patients in the sham control group (P=0.65). The change in the number of prescribed medication classes was −0.3 (±1.4) for patients in the RDN group versus −0.2 (±0.9) for patients in the sham control group (P=0.22) at 36 months. The RDN group exhibited a trend toward a lower AHM burden, which was not statistically significant at 24 and 36 months. The AHM burden in patients undergoing RDN decreased from baseline to 36 months (MEDINDEX1: 5.1 to 4.6; MEDINDEX2: 28.8 to 25.2; MEDINDEX3: 36.4 to 31.8; MEDINDEX4: 10.2 to 8.4). 30 Global SYMPLICITY Registry The GSR (Global SYMPLICITY Registry; NCT01534299) is a prospective, multicenter, observational, single‐arm, and open‐label registry study to document the long‐term safety and efficacy of RDN using the Medtronic RDN system (first‐generation single‐electrode Symplicity Flex or the second‐generation 4‐electrode Symplicity Spyral catheter; Medtronic plc, Santa Rosa, CA) in a real‐world setting. GSR DEFINE (Global SYMPLICITY Registry Denervation Findings in Real World) is a continuation of GSR, aiming to enroll ≈5000 patients with hypertension aged ≥18 years from over 300 sites worldwide, with an extended follow‐up of 5 years. Until 2018, 31 2237 patients from 45 countries treated with the SYMPLICITY Flex catheter were enrolled, of which 1742 participants had 36‐month follow‐up data available. Office SBP decreased by −16.5±28.6 mm Hg from baseline (P<0.001), while the ambulatory SBP decreased by −8.0±20.0 mm Hg (P<0.001) with no long‐term safety concern. The prescribed AHM classes decreased from 4.5±1.4 at baseline to 4.4±1.4, 4.4±1.5, and 4.4±1.5 at 1, 2, and 3 years, respectively (P<0.001). Using β blockers, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, diuretics, α‐adrenergic blockers, centrally acting sympatholytics, and direct renin inhibitors decreased, whereas the concomitant use of aldosterone antagonists increased. By March 2023, the GSR DEFINE enrolled 3332 participants. 32 In an analysis investigating whether the long‐term efficacy of RDN was associated with baseline AHM use, 2746 patients from the GSR DEFINE cohort were included, 22.3% of whom were treated with a Spyral catheter and 77.7% with a Symplicity Flex catheter. The office and ambulatory SBP reductions from baseline were −16.7±28.6 and −9.1±20.2 mm Hg at 36 months, respectively (P<0.0001). RDN consistently reduced BP regardless of the baseline number and types of AHMs. The average number of AHM classes decreased from 4.6±1.4 at baseline to 4.3±1.5 at 36 months (P<0.001), the prescribed numbers of AHM classes remained the same in 46.8%, decreased in 31.2%, and increased in 22.0% patients through the 36 months. A large proportion of patients taking ≥4 medication classes at baseline exhibited a decrease in the number of AHMs at 36 months compared with those taking 0 to 3 medication classes (20.9% versus 7.3%; P<0.0001). 32 AHM adherence was not analyzed through toxicological assessments in this real‐world study. Other Studies With Long‐Term Follow‐Up Sesa‐Ashton et al 33 recruited 66 patients previously enrolled in RDN trials using the Symplicity Flex Catheter System (Medtronic) in Australia. These patients completed a long‐term follow‐up assessment with a mean duration of 8.8±1.2 years. Ambulatory BP was reduced by −12.1±21.6/−8.8±12.8 mm Hg (P<0.0001 for both) compared with baseline (ambulatory BP, 145.2±17.3/81.2±12.2 mm Hg). At long‐term follow‐up, 62.7% of participants exhibited with high‐normal or normal BP, of which 15 patients achieved an optimal SBP of <120 mm Hg compared with the 2 patients at baseline. The results also demonstrated that the BP‐lowering efficacy of RDN was consistent in patients with or without chronic kidney disease and diabetes at baseline. Patients with isolated systolic hypertension exhibited similar BP reduction compared with those with systolic–diastolic hypertension (P=0.4390). At long‐term follow‐up, the daily defined doses of prescribed AHMs were reduced from 5.0±2.8 at baseline to 4.1±2.1 (P=0.0045). The reduction in AHM burden was primarily attributed to a decreased number of β blockers and moxonidine use (P=0.042). Al Ghorani et al 34 conducted a single‐arm, single‐center study on 107 patients with resistant hypertension in Germany, of which 39 were available for follow‐up. These patients underwent RDN using a Symplicity Flex single‐electrode catheter system (Medtronic) and were followed up for a mean duration of 9.4±0.7 years. At 10‐year follow‐up, the ambulatory BP decreased by −16.2±17.3/−5.5±13.0 mm Hg (P<0.001 and P<0.027, respectively) with a similar number of AHMs (4.9±1.4 at baseline versus 4.5±1.2 at follow‐up; P=0.087). Vogt et al 35 performed a long‐term follow‐up (9.3 [interquartile range, 8.5–10.1] years) on 72 patients previously enrolled in a local RDN registry in Germany. These patients were treated using the Symplicity Flex catheter system (Medtronic) between 2011 and 2014. Ambulatory BP decreased gradually, with a reduction of −10.3/−8.4 mm Hg at long‐term follow‐up (P<0.01). The number of AHMs decreased from 5.4±1.5 to 4.8±1.6 at follow‐up (P<0.01). The proportion of patients prescribed renin–angiotensin–aldosterone system blockers, calcium antagonists, β blockers, and diuretics remained constant. The proportion of centrally acting sympatholytic drugs decreased significantly (53.7% to 34.4%, P<0.01). Conversely, the proportion of patients taking mineralocorticoid receptor antagonists increased (9.3% versus 29.6%, P<0.01). Zeijen et al 36 conducted a single‐center, single‐arm registry study in the Netherlands, including 72 patients undergoing RDN to treat resistant hypertension, and the yearly follow‐up continued for 5 years. These patients were treated using either the Paradise system (ReCor Medical, Inc, Palo Alto, CA), the Covidien OneShot system (Covidien, Campbell, CA), the Vessix system (Boston Scientific, Natick, MA), the St. Jude EnligHTN system, the Symplicity Flex system (Medtronic, Inc, Minneapolis, MN) or the multielectrode Symplicity Spyral system (Medtronic, Inc). The BP‐lowering effects were analyzed using linear mixed‐effects models. As derived from the mixed model, the estimated ambulatory daytime SBP reduction 5 years after RDN was −20.9/−8.3 mm Hg compared with baseline (P<0.0001). The number of AHMs and the defined daily doses remained stable over time (P=0.87). Gaps Between Current Evidence and Patient Perspectives Patient involvement was associated with increased decision quality and improved health outcomes and is increasingly encouraged in treatment decisions. Patient perspectives are determined by socioeconomic factors, racial differences, sex discrimination, educational levels, and other factors, which may pose a challenge for doctors to integrate their preferences if patients have unreasonable expectations. 37 , 38 Several studies have been recently conducted regarding patient preferences for catheter‐based RDN to treat uncontrolled hypertension. Schmieder et al conducted a questionnaire‐based cross‐sectional survey of 1011 German hypertensive patients. 8 The results revealed that 33.2% of the investigated patients preferred RDN. Notably, 79.3% of patients supporting RDN expected that RDN could lower their BP by at least 15 mm Hg. Among those prone to RDN, 72.9% of patients were willing to undergo RDN if no more drugs were to be taken after RDN, 11.6% would choose RDN if they could take 2 pills fewer after RDN, and 7.7% would prefer RDN if they could take 3 to 4 pills fewer after RDN. Similar results were obtained in our cross‐sectional survey conducted in Chengdu, China. 7 Of the 402 patients included, 32.6% expressed a willingness to choose RDN, 56.5% would prefer RDN if they could take 1 pill fewer, 32.8% would choose RDN if they could take 2 pills fewer after RDN, and 68.8% would prefer RDN therapy if the efficacy could last for at least 15 years. Considering that the primary end point was frequently assessed at 2 to 6 months in most randomized controlled trials of RDN, we selected 6 months as the time point to separately describe the changes in AHM after RDN in this review (Table). In both studies with follow‐ups ≤6 months 11 , 12 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 25 , 26 , 28 and >6 months, 22 , 23 , 24 , 25 , 30 , 31 , 32 , 33 , 34 , 35 , 36 randomized controlled trials demonstrated that patients undergoing RDN exhibited lower BP levels with a similar AHM burden or similar BP levels with fewer AHMs than the sham control group. In studies with follow‐ups ≤6 months, AHM use increased or remained generally consistent in patients undergoing RDN, which may be attributed to the prespecified study process. In studies with follow‐ups >6 months, the BP‐lowering efficacy of RDN was consistent with a decreasing or similar AHM burden compared with baseline conditions, except for the 36‐month results in the SPYRAL HTN‐ON MED trial (Figure). However, the magnitude of AHM burden reduction was not significant, and a significant difference existed between current evidence on medication changes after RDN and patient expectations, posing additional challenges for the clinical application of RDN. Table 1BP‐Lowering Efficacy and Medication Changes in RDN TrialsTrial (or author), year publishedFollow‐up periodSample size, nRDN systemBP‐lowering efficacyMedication changesAHM adherenceSPYRAL HTN‐ON MED full cohort, 2023 11 6 moRDN (n=206), sham (n=131)Spyral24 h SBP between‐group difference −1.9 (−4.4 to 0.5), P=0.12. 24 h nighttime SBP between‐group difference −3.7 (−6.5 to −0.9), P=0.0095 Numbers of AHMs: 1.9±0.9 (RDN), 2.1±0.9 (sham), P=0.0085. Medication burden: 2.9±2.7 (RDN), 3.5±3.2 (sham), P=0.043. RDN: 17% increased, 16% decreased; sham: 26% increased, 10% decreased RDN: number of AHMs from baseline to 6 mo 1.9±0.8 versus 1.9±0.9, AHM burden from baseline to 6 mo 2.8±2.5 versus 2.9±2.7 ≈60% in both groupsSPYRAL HTN‐ON MED pilot, 2018 12 6 moRDN (n=38), sham (n=42)Spyral 24 h SBP between‐group difference −7.4 (−12.5 to −2.3), P=0.0051 24 h diastolic BP between‐group difference −4.1 (−7.8 to −0.4), P=0.0292 Number of AHMs: 2.13±1.40 (RDN), 2.21±1.05 (sham), P=0.17RDN: 60.5%, sham: 64.3%, P=0.82SPYRAL HTN‐ON MED pilot, 2022 14 36 moRDN (n=38), sham (n=42)Spyral 24 h SBP between‐group difference −10.0 (−16.6 to −3.3), P=0.039. 24 h diastolic BP between‐group difference −5.9 (−10.1 to −1.8), P=0.0055 Number of AHMs: RDN 3.03±1.20, sham 3.05±1.43, P=0.76 AHM burden: RDN 2.13±1.15, sham 2.55±2.19, P=0.26. RDN: number of AHMs increased from 2.13±1.40 at baseline to 3.03±1.20 at 36 mo, AHM burden increased from 1.43±1.19 at baseline to 2.13±1.15 at 36 mo RDN: 77%, sham: 93%RADIANCE‐HTN SOLO, 2018 15 2 moRDN (n=74), sham (n=72)Paradise24 h daytime SBP between‐group difference adjusted for baseline BP: −6.3 mm Hg, 95% CI, −9.4 to −3.1, P=0.0001…Not assessedRADIANCE II, 2023 16 2 moRDN (n=150), sham (n=74)Paradise24 h daytime SBP difference −6.3 mm Hg (95% CI, −9.3 to −3.2 mm Hg; P<0.001)……RADIANCE‐HTN TRIO 2021 17 2 moRDN (n=69), sham (n=67)Paradise24 h daytime SBP difference: −4.5 mm Hg (95% CI: −8.5 to −0.3 mm Hg; P=0.022)…RDN: 82.0%, sham: 82.0%, P=0.99RADIANCE‐HTN patient‐level pooled analysis, 2023 18 2 moRDN (n=293), sham (n=213)Paradise24 h daytime SBP between‐group difference −5.9 (−8.1 to −3.8), P<0.001……RADIANCE‐HTN SOLO, 2019 19 6 moRDN (n=74), sham (n=72)Paradise24 h daytime SBP between‐group difference adjusted for baseline BP: −2.3 mm Hg, 95% CI, −6.0 to 1.5, P=0.242; between‐group difference adjusted for baseline BP and number of AHMs: −4.3 mm Hg, 95% CI, −7.9 to −0.6, P=0.024Number of AHMs: 0.9±0.9 (RDN), 1.3±0.9 (sham) (P=0.010), defined daily dose ratio: 1.3±1.5 (RDN), 2.0±1.8 (sham) (P=0.018), AHM load index: 0.5±0.5 (RDN), 0.7±0.6 (sham) (P=0.014). RDN: AHM increased in 65.2% of patients post‐RDN, and sham: AHM increased in 84.5% of patients post‐RDN (P=0.008)Not assessedRADIANCE‐HTN TRIO, 2022 20 6 moRDN (n=69), sham (n=67)Paradise24‐h daytime SBP difference −2.5 mm Hg (95% CI, −6.7 to 1.7 mm Hg; P=0.25)AHM was added from baseline to 6 mo (RDN: 0.7±1.0, sham:1.1±1.1, P=0.045)RDN: 71.4%, sham: 78.2%RADIANCE‐HTN patient‐level pooled analysis, 2024 21 6 moRDN (n=293), sham (n=213)Paradise24 h daytime SBP between‐group difference adjusted for baseline BP: −1.9 mm Hg, 95% CI: −4.8 to 1.0, P=0.33; between‐group difference adjusted for baseline BP and number of AHMs: −3.0 mm Hg, 95% CI, −5.7 to −0.2, P=0.033Changes in the number of AHMs from baseline to 6 mo: RDN 1.1±1.0, sham 1.3±1.0, P=0.001; changes in defined daily dose from baseline to 6 mo: RDN 1.3±1.6, sham 1.6±1.6, P=0.001; change in AHM load index from baseline to 6 months: RDN 0.5±0.6, sham 0.6±0.6, P=0.001RDN: 83.3%, sham: 83.8% (P=0.47)RADIANCE‐HTN SOLO, 2020 22 12 monthsRDN (n=65), sham (n=67)ParadiseDaytime ambulatory SBP: between‐group difference adjusted for baseline BP and number of AHMs: −2.3 mm Hg, 95% CI, −5.9 to 1.3 mm Hg, P=0.201.Office SBP: adjusted between‐group difference: −6.3 mm Hg, 95% CI, −11.1 to −1.5 mm Hg, P=0.010 Total number of AHMs: RDN: 1.0 (0.0–3.0), sham: 1.4 (0.0–3.0), P=0.015; defined daily dose: RDN: 1.4±1.4, sham: 2.2±1.8, P=0.007; AHM load index: RDN: 0.5±0.5, sham: 0.8±0.6, P=0.009 RDN: from screening to 12 mo, number of AHMs: 1.2±0.7 to 1.0±0.8, defined daily dose: 1.9±2.3 to 1.4±1.4, antihypertensive load index: 0.7±1.0 to 0.5±0.5 Not assessedRADIANCE‐HTN TRIO, 2022 23 24 moRDN (n=51), sham (n=49)ParadiseOffice SBP: −14.6/−8.4 mm Hg from screening to 24 mo −9.3/−5.0 mm Hg from baseline to 24 moMean number of AHMs in the RDN group was 3.9 at screening and 3.4 at 24 moNot availableRADIANCE‐HTN SOLO, 2022 24 36 moRDN (n=51)ParadiseOffice SBP: −17.7/−11.3 mm Hg from baseline to 36 mo; −8.4/−4.4 mm Hg from screening to 36 mo From baseline to 36 mo: addition 1.3 AHM; From screening to 36 mo: 1.2±0.7 versus 1.3±0.8, P=0.461 Not assessedTARGET BP OFF‐MED, 2023 25 2 moRDN (n=50), sham (n=56)Peregrine24 h SBP: RDN: −2.9±7.4 mm Hg (P=0.009), sham: −1.4±8.6 mm Hg (P=0.25) (between‐group difference: 1.5 mm Hg, 95% CI, −4.8 to 1.7 mm Hg, P=0.27)…Not availableTARGET BP OFF‐MED, 2023 25 6 moRDN (n=50), sham (n=56)Peregrine24 h SBP: RDN: −13.9±11.6 mm Hg (P<0.0001), sham: −13.4±12.9 mm Hg (P<0.0001) (between‐group difference: −0.55 mm Hg, 95% CI, −5.7 to 4.6 mm Hg, P=0.696)The mean number of AHMs (RDN: 0.96 vs sham: 1.40, P=0.035), defined daily doses (RDN: 1.20 vs sham: 2.00, P=0.012), the proportion of patients on ≥2 AHM (RDN: 26% vs sham: 52%, P=0.009)Not availableTARGET BP OFF‐MED, 2023 25 12 moRDN (n=50), sham (n=56)Peregrine 24 h SBP: between‐group difference 5.3 mm Hg, 95% CI, −0.1 to 10.7, P=0.0775. Office SBP: between‐group difference: 2.2 mm Hg, 95% CI, −4.5 to 8.9, P=0.6823 Mean number of AHMs (RDN: 1.10 vs sham: 1.60, P=0.0081), defined daily doses (RDN: 1.50 vs sham: 2.30, P=0.0168), proportion of patients on ≥2 AHM (RDN: 29% vs sham: 57%, P=0.005)Not availableTARGET BP‐I, 2024 26 3 moRDN (n=148), sham (n=153)Peregrine24 h SBP: RDN: −10.0±14.2, sham: −6.8±12.1 (between‐group difference: −3.2 mm Hg, 95% CI, −6.3 to 0 mm Hg, P=0.0487) Defined daily doses: RDN: 5.3±2.6, sham: 5.3±2.4 Medication index: RDN 2.1±1.1, Sham 2.1±1.0. Change in number of AHM between baseline and 3 mo: RDN: 0.014±0.375, sham: 0.000±0.436 RDN: 51%, sham: 49% (P=0.765)SMART, 2023 28 6 mo RDN (n=110), sham (n=110) SyMap Control rate of office SBP: RDN: 95.4%, sham: 92.8%, P=0.429. 24 h SBP reduction: RDN: −10.8 mm Hg, sham −10.0 mm Hg, P=0.685 Change of AHM composite index: RDN: 9.17 at baseline to 13.16 at 6 mo; sham: 9.04 at baseline to 16.03 at 6 mo (composite index change: 4.37 vs 7.61, P<0.01)RDN: 89.9%, sham: 90.9%SYMPLICITY HTN‐3, 2022 30 36 moRDN (n=219), sham (n=134)Symplicity Flex Office SBP: adjusted between‐group difference −22.1 mm Hg [95% CI, −27·2 to −17·0], P≤0.0001 24 h SBP: adjusted between‐group difference: −16.5 mm Hg [95% CI, −20.5 to −12.5], P≤0.0001 AHM burden MEDINDEX1: RDN: 4.6, sham: 5.2, P=0.14; MEDINDEX2: RDN: 25.2, sham: 29.6, P=0.20; MEDINDEX3: RDN: 31.8, sham 37.7, P=0.20; MEDINDEX4: RDN: 8.4, sham: 9.7, P=0.005; RDN: from baseline to 36 mo, MEDINDEX1: 5.1 to 4.6; MEDINDEX2: 28.8 to 25.2; MEDINDEX3: 36.4 to 31.8; MEDINDEX4: 10.2 to 8.4Not assessedGlobal SYMPLICITY Registry, 2019 31 36 moRDN (n=1742)Symplicity FlexOffice SBP: −16.5±28.6 mm Hg (P<0.001), ambulatory SBP: −8.0±20.0 mm Hg (P<0.001).AHM classes: 4.5±1.4 at baseline to 4.4±1.5 (P<0.001)Not assessedGSR DEFINE 2023 32 36 moRDN (n=2746)Symplicity Flex (77.7%) and Spyral (22.3%)Office SBP: −16.7±28.6 mm Hg (P<0.001), ambulatory SBP: −9.1±20.2 mm Hg (P<0.001)AHM classes: 4.6±1.4 at baseline to 4.3±1.5 (P<0.001); the prescribed number of AHM classes remained the same in 46.8% of patients, decreased in 31.2%, and increased in 22.0%Not assessedSesa‐Ashton et al, 2023 33 8.8±1.2 yearsRDN (n=66)Symplicity FlexAmbulatory BP: −12.1±21.6/−8.8±12.8 mm Hg (P<0.0001 for both)Daily defined doses: 5.0±2.8 at baseline to 4.1±2.1 at follow‐up, P=0.0045Not assessedAl Ghorani et al, 2023 34 9.4±0.7 yRDN (n=39)Symplicity FlexAmbulatory BP: −16.2±17.3/−5.5±13.0 mm Hg (P<0.001 and P<0.027, respectively)Number of AHMs: 4.9±1.4 at baseline to 4.5±1.2 at follow‐up, P=0.087Not assessedVogt et al, 2023 35 9.3 y [interquartile range, 8.5–10.1]RDN (n=72)Symplicity FlexAmbulatory BP: −10.3/−8.4 mm Hg (P<0.01)Number of AHM: from 5.4±1.5 at baseline to 4.8±1.6 at follow‐up (P<0.01)Not assessedZeijen et al, 2022 36 5 yRDN (n=72)Paradise, Covidien OneShot, Vessix, St. Jude EnligHTN, Symplicity Flex, Symplicity SpyralAmbulatory daytime SBP: −20.9/−8.3 mm Hg (P<0.0001)Number of AHMs defined daily doses remained stable over time (P=0.87)Not assessedAHM indicates antihypertensive medication; BP, blood pressure; RDN, renal denervation; and SBP, systolic blood pressure. BP‐Lowering Efficacy and Medication Changes in RDN Trials Numbers of AHMs: 1.9±0.9 (RDN), 2.1±0.9 (sham), P=0.0085. Medication burden: 2.9±2.7 (RDN), 3.5±3.2 (sham), P=0.043. RDN: 17% increased, 16% decreased; sham: 26% increased, 10% decreased RDN: number of AHMs from baseline to 6 mo 1.9±0.8 versus 1.9±0.9, AHM burden from baseline to 6 mo 2.8±2.5 versus 2.9±2.7 24 h SBP between‐group difference −7.4 (−12.5 to −2.3), P=0.0051 24 h diastolic BP between‐group difference −4.1 (−7.8 to −0.4), P=0.0292 24 h SBP between‐group difference −10.0 (−16.6 to −3.3), P=0.039. 24 h diastolic BP between‐group difference −5.9 (−10.1 to −1.8), P=0.0055 Number of AHMs: RDN 3.03±1.20, sham 3.05±1.43, P=0.76 AHM burden: RDN 2.13±1.15, sham 2.55±2.19, P=0.26. RDN: number of AHMs increased from 2.13±1.40 at baseline to 3.03±1.20 at 36 mo, AHM burden increased from 1.43±1.19 at baseline to 2.13±1.15 at 36 mo Total number of AHMs: RDN: 1.0 (0.0–3.0), sham: 1.4 (0.0–3.0), P=0.015; defined daily dose: RDN: 1.4±1.4, sham: 2.2±1.8, P=0.007; AHM load index: RDN: 0.5±0.5, sham: 0.8±0.6, P=0.009 RDN: from screening to 12 mo, number of AHMs: 1.2±0.7 to 1.0±0.8, defined daily dose: 1.9±2.3 to 1.4±1.4, antihypertensive load index: 0.7±1.0 to 0.5±0.5 From baseline to 36 mo: addition 1.3 AHM; From screening to 36 mo: 1.2±0.7 versus 1.3±0.8, P=0.461 24 h SBP: between‐group difference 5.3 mm Hg, 95% CI, −0.1 to 10.7, P=0.0775. Office SBP: between‐group difference: 2.2 mm Hg, 95% CI, −4.5 to 8.9, P=0.6823 Defined daily doses: RDN: 5.3±2.6, sham: 5.3±2.4 Medication index: RDN 2.1±1.1, Sham 2.1±1.0. Change in number of AHM between baseline and 3 mo: RDN: 0.014±0.375, sham: 0.000±0.436 RDN (n=110), sham (n=110) Control rate of office SBP: RDN: 95.4%, sham: 92.8%, P=0.429. 24 h SBP reduction: RDN: −10.8 mm Hg, sham −10.0 mm Hg, P=0.685 Office SBP: adjusted between‐group difference −22.1 mm Hg [95% CI, −27·2 to −17·0], P≤0.0001 24 h SBP: adjusted between‐group difference: −16.5 mm Hg [95% CI, −20.5 to −12.5], P≤0.0001 AHM indicates antihypertensive medication; BP, blood pressure; RDN, renal denervation; and SBP, systolic blood pressure. Gaps exist between current evidence on AHM use and patient expectations AHM indicates antihypertensive medications; BP, blood pressure; and RDN, renal denervation. Our review has some limitations that must be acknowledged. A quantitative evaluation of AHM burden changes after RDN could not be performed due to the different indices and definitions used in these studies. Additionally, BP levels may be influenced by changes in prescribed AHM classes during the follow‐up as suggested in our review, thereby complicating the assessment of BP‐lowering efficacy. The updated meta‐analysis results indicated that RDN was associated with a significant but mild BP reduction during a mean follow‐up of 5 months. 39 Kjeldsen et al 40 observed that the BP‐lowering effect of RDN corresponds to that of 1 antihypertensive drug. It seems that the magnitude of the RDN‐induced BP reduction could be replaced by adding 1 more drug. However, in the SPYRAL HTN‐ON MED trial, the office SBP in the RDN and sham control groups remained >140 mm Hg at 36 months, despite the discretion of the physicians to titrate AHM after 6 months, suggesting physician inertia to aggressively control BP to reach the target or patients' intolerance or nonadherence. This situation may be even worse in real‐world clinical practice. In the long term, the BP reductions improved progressively after RDN and reached −12.7 to −14.8 mm Hg in ambulatory SBP during a mean follow‐up of 7.7±2.8 years. 6 Office SBP decreased by ≈20 mm Hg from baseline to 36 months with the addition of 1 more drug in the SPYRAL HTN‐ON MED 14 and RADIANCE HTN‐SOLO trials. 24 Indeed, a 5‐mm Hg reduction in office SBP was associated with a 10% risk reduction of major cardiovascular events. 41 Despite the addition of more drugs after RDN, the potential cardiovascular benefits could multiply. The above updated information should be provided adequately in a shared decision‐making process. Moreover, first‐generation RDN devices have been used in most long‐term studies, and further research is required to determine whether contemporary second‐generation devices are associated with further reduction in AHM use in the long term. Besides, patient perspectives may differ in survey studies and clinical scenarios, and adequate communication between health care providers and patients and continuous efforts to improve the RDN procedure are important to alleviate and bridge the gaps between evidence and patient expectations. Conclusions Randomized controlled trials demonstrated that patients undergoing RDN exhibited lower BP levels with a similar AHM burden or similar BP levels with fewer AHMs compared with the sham control group. In studies with follow‐ups ≤6 months, AHM use increased or remained generally consistent in patients undergoing RDN, which may be attributed to the prespecified study process. In studies with follow‐ups >6 months, the BP‐lowering efficacy of RDN was consistent with a decreasing or similar AHM burden compared with baseline conditions, except for the 36‐month results in the SPYRAL HTN‐ON MED trial. Huge gaps exist between current evidence on medication changes after RDN and patient expectations, which may be addressed by adequate communication in a shared decision‐making process and further improvement of the RDN procedure. Moreover, novel evaluation methodologies for assessing medication burden changes, incorporating adherence to AHMs and modifications in drug classes, may be required to evaluate the impact of RDN on medication usage in the future. Disclosures None.